Evolving meningococcal immunization strategies

References

• Gotschlich EC, Liu TY, Artenstein MS. Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides. J Exp Med 1969;129:1349-65
   PubMed Web of Science ®Google Scholar
• Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med 1969;129:1367-84
   PubMed Web of Science ®Google Scholar
• Goldblatt D. Conjugate vaccines. Clin Exp Immunol 2000;119:1-3
   PubMed Web of Science ®Google Scholar
• Costantino P, Viti S, Podda A, et al. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 1992;10:691-8
   PubMed Web of Science ®Google Scholar
• Richmond PC, Miller E, Borrow R, et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 1999;179:1569-72
   PubMed Web of Science ®Google Scholar
• Richmond P, Borrow R, Findlow J, et al. Evaluation of de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming and bactericidal activity against O-acetylated and de-O-acetylated serogroup C strains. Infect Immun 2001;69:2378-82
   PubMed Web of Science ®Google Scholar
• MacLennan JM, Shackley F, Heath PT, et al. Safety, immunogenicity and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants. A randomised controlled trial. JAMA 2000;283:2795-801
   PubMed Web of Science ®Google Scholar
• Richmond P, Borrow R, Goldblatt D, et al. Ability of three different meningococcal C conjugate vaccines to induce immunological memory after a single dose in UK toddlers. J Infect Dis 2001;183:160-3
   PubMed Web of Science ®Google Scholar
• Burrage M, Robinson A, Borrow R, et al. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun 2002;70:4946-54
   PubMed Web of Science ®Google Scholar
• Pichichero M, Casey J, Blatter M, et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr Infect Dis J 2005;24:57-62
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forstén A, Boutriau D, et al. A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years. Hum Vaccin Immunother 2012;8:1882-91
   PubMed Web of Science ®Google Scholar
• Abdelnour A, Silas PE, Lamas MR, et al. Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: results of an open-label, randomized, phase 3b controlled study in healthy infants. Vaccine 2014;32:965-72
   PubMed Web of Science ®Google Scholar
• Holst J, Oster P, Arnold R, et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother 2013;9:1241-53
   PubMed Web of Science ®Google Scholar
• Martin NG, Snape MD. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn? Expert Rev Vaccines 2013;12:837-58
   PubMed Web of Science ®Google Scholar
• Gray SJ, Trotter CL, Ramsay ME, et al. The epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: the contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 2006;55:887-96
   PubMed Web of Science ®Google Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001;20(Suppl 1):S58-67
   PubMed Web of Science ®Google Scholar
• Romero ER, Penas VN, Rodriguez JAT, et al. Implementation and impact of a meningococcal C conjugate vaccination program in 13- to 25-year-old individuals in Galicia, Spain. J Public Health 2011;19:409-15
   Google Scholar
• Immunisation against infectious disease: the green book. Available from: https://www.gov.uk/government/organisations/public-health-england/series/immunisation-against-infectious-disease-the-green-book
   Google Scholar
• Maiden MCJ, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002;359:1829-31
   PubMed Web of Science ®Google Scholar
• Maiden MC, Ibarz-Pavón AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008;197:737-43
   PubMed Web of Science ®Google Scholar
• Trotter C, Andrews N, Kaczmarski E, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004;364:365-7
   PubMed Web of Science ®Google Scholar
• Campbell H, Borrow R, Salisbury D, Miller E. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 2009;27S:B20-9
   Google Scholar
• Auckland C, Gray S, Borrow R, et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the UK. J Infect Dis 2006;194:1745-52
   PubMed Web of Science ®Google Scholar
• Southern J, Borrow R, Andrews N, et al. Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with a 7-valent pneumococcal conjugate vaccine and a combination DTaP5/Hib/IPV vaccine in healthy UK infants. Clin Vaccine Immunol 2009;16:194-9
   PubMed Web of Science ®Google Scholar
• Borrow R, Andrews N, Findlow H, et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine at 12 to 15 months of age in healthy UK infants primed with two doses of one of three monovalent meningococcal serogroup C vaccines. Clin Vaccine Immunol201017154159
   PubMed Web of Science ®Google Scholar
• Trotter C, Borrow R, Andrews N, Miller E. Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. Vaccine 2003;21:1094-8
   PubMed Web of Science ®Google Scholar
• Trotter CL, Borrow R, Findlow J, et al. Seroprevalence of antibodies against serogroup C meningococci in England in the post-vaccination era. Clin Vaccine Immunol 2008;15:1694-8
   PubMed Web of Science ®Google Scholar
• Ishola D, Borrow R, Findlow H, et al. Prevalence of serum bactericidal antibody to serogroup C Neisseria meningitidis in England, a decade after vaccine introduction. Clin Vaccine Immunol 2012;19:1126-30
   PubMed Web of Science ®Google Scholar
• Findlow H, Borrow R, Andrews N, et al. Immunogenicity of a single dose of meningococcal group C conjugate vaccine, at 3 months of age in healthy infants in the United Kingdom. Pediatr Infect Dis J 2012;31:616-22
   PubMed Web of Science ®Google Scholar
• Cano R, Larrauri A, Mateo S, et al. Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision. Euro Surveill 2004;9:11-15
   PubMedGoogle Scholar
• Public Health England. Changes to the Meningococcal C conjugate (MenC) vaccine schedule 2013. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/212700/MenC_QandAs_for_healthcare_professionals.pdf
   Google Scholar
• van der Ende A, Spanjaard L. Bacteriële meningitis in Nederland, 2001–2010. Infectieziekten Bulletin 2011;22:189-93
   Google Scholar
• European Centre for Disease Prevention and Control. Surveillance report on invasive bacterial disease in Europe for 2008–2009. European Centre for Disease Prevention and Control 2011 July 18. Available from: http://www.ecdc.europa.eu/en/publications/Publications/1107_SUR_IBD_2008-09.pdf
   Google Scholar
• Stoof SP, van der Klis FRM, van Rooijen DM, et al. Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagers. PLoS One 2014;9:e100651
   PubMed Web of Science ®Google Scholar
• Patel M. Meningococcal disease in Australia; looking at the past, thinking of the future. Commun Dis Intell 1997;21:233-6
   PubMedGoogle Scholar
• Booy R, Jelfs J, El Bashir H, Nissen MD. Impact of meningococcal C conjugate vaccine use in Australia. Med J Aust 2007;186:108-9
   PubMed Web of Science ®Google Scholar
• Lahra MM, Enriquez RP. Australian Meningococcal Surveillance Programme annual report, 2012. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-cdi3703-pdf-cnt.htm/$FILE/cdi3703e.pdf
   Google Scholar
• Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999;180:1894-901
   PubMed Web of Science ®Google Scholar
• Deeks S, Kertesz D, Ryan A, et al. Surveillance of invasive meningococcal disease in Canada, 1995-1996. Can Commun Dis Rep 1997;23:121-5
   PubMedGoogle Scholar
• Diermayer M, Hedberg K, Hoesly F, et al. Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain. JAMA 1999;281:1493-7
   PubMed Web of Science ®Google Scholar
• Law DK, Lorange M, Ringuette L, et al. Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). J Clin Microbiol 2006;44:2743-9
   PubMed Web of Science ®Google Scholar
• Zhou J, Lefebvre B, Deng S, et al. Invasive serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: persistence of the ST-269 clone since it first emerged in 2003. J Clin Microbiol 2012;50:1545-51
   PubMed Web of Science ®Google Scholar
• Bettinger JA, Deeks SL, Halperin SA, et al. Controlling serogroup B invasive meningococcal disease: the Canadian perspective. Expert Rev Vaccines 2013;12:505-17
   PubMed Web of Science ®Google Scholar
• Gilca R, Deceuninck G, Lefebvre B, et al. The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains. PloS One 2012;7:e50659
   PubMed Web of Science ®Google Scholar
• Bettinger JA, Scheifele DW, Le Saux N, et al. The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J 2013;32:e20-5
   PubMed Web of Science ®Google Scholar
• Law DK, Stoltz J, Henderson AM, Tsang RS. Antigenic and genetic characterization of serogroup C meningococci isolated from invasive meningococcal disease cases in Canada from 1999 to 2003. Can J Microbiol 2005;51:523-30
   PubMed Web of Science ®Google Scholar
• Keyserling H, Papa T, Koranyi K, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005;159:907-13
   PubMed Web of Science ®Google Scholar
• Vu DM, Welsch JA, Zuno-Mitchell P, et al. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis 2006;193:821-8
   PubMed Web of Science ®Google Scholar
• CDC. National vaccination coverage among adolescents aged 13–17 years—United States, 2006. MMWR 2007;56:885-8
   Google Scholar
• CDC. National and State vaccination coverage among adolescents aged 13–17 years — United States, 2012. MMWR 2013;62:685-93
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013;62(RR-2):1-28
   PubMed Web of Science ®Google Scholar
• Clark TA, Stern EJ, Pondo T, et al. The effect of quadrivalent (A, C, Y W-135) meningococcal conjugate vaccine on serogroup-specific carriage of Neisseria meningitidis. 16th International Pathogenic Neisseria Conference; Beurs World Trade Centre, Rotterdam, The Netherlands; 7th–12th September 2008; O52 2008. p. 68
   Google Scholar
• Update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2009;36(ACS-3):1-40
   Google Scholar
• Snape MD, Kelly DF, Salt P, et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis 2006;43:1387-94
   PubMed Web of Science ®Google Scholar
• Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009;9:213-20
   PubMed Web of Science ®Google Scholar
• Bettinger JA, Scheifele DW, Halperin SA, et al. Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: interim analysis. Vaccine 2012;30:4023-7
   Google Scholar
• Li YA, Tsang R, Desai S, Deehan H. Enhanced surveillance of invasive meningococcal disease in Canada, 2006-2011. Can Commun Dis Rep 2014.40-9. Available from: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/14vol40/dr-rm40-09/dr-rm40-09-surv-eng.php
   Google Scholar
• Sadarangani M, Scheifele DW, Halperin SA, et al. The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012. Clin Infect Dis 2014;59(9):1208-15
   PubMed Web of Science ®Google Scholar
• Bettinger J, Scheifele DW, Le Saux N, et al. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr Infect Dis J 2009;28:220-4
   PubMed Web of Science ®Google Scholar
• Kinlin LM, Jamieson F, Brown EM, et al. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006. Vaccine 2009;27:1735-40
   PubMed Web of Science ®Google Scholar
• Patrick DM, Champagne S, Goh SH, et al. Neisseria meningitidis carriage during an outbreak of serogroup C disease. Clin Infect Dis 2003;37:1183-8
   Google Scholar
• Gilca R, De Wals P, Costa JA, et al. Longitudinal study of Neisseria meningitidis oropharyngeal carriage in adolescents and young adults in Québec City, Canada. European Meningococcal Disease Society (EMGM) Conference; September 17th–19th 2013; Bad Loipersdorf, Austria; 2013. p. 64
   Google Scholar
• Rüttimann RW, Gentile A, Parra MM, et al. A consensus statement: meningococcal disease among infants, children and adolescents in Latin America. Pediatr Infect Dis J 2014;33:284-90
   Google Scholar
• Pan American Health Organization. Informe Regional de SIREVA II, 2012 Datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis, en procesos invasores. OPS. Documentos tecnicos, Tecnologias Esenciales de Salud, Washington, DC; 2013. Available from: http://www.paho.org/hq/index.php?option=com_content&view=category&id=3609&layout=blog&Itemid=3953&lang=pt
   Google Scholar
• de Lemos AP, Yara TY, Gorla MC, et al. Clonal distribution of invasive Neisseria meningitidis serogroup C strains circulating from 1976 to 2005 in greater Sao Paulo, Brazil. J Clin Microbiol 2007;45:1266-73
   PubMed Web of Science ®Google Scholar
• Sáfadi MA, de los Monteros LE, López EL, et al. The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative. Expert Rev Vaccines 2013;12:903-15
   PubMed Web of Science ®Google Scholar
• Lingappa JR, Al-Rabeah AM, Hajjeh R, et al. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis 2003;9:665-71
   PubMed Web of Science ®Google Scholar
• Safadi MAP, Berezin E, Arlant LHF. Meningococcal Disease: epidemiology and early effects of immunization programs. J Ped Infect Dis 2014;3:91-3
   Google Scholar
• López EL, Debbag R. [Meningococcal disease: always present. Serogroup changes in the Southern Cone]. Rev Chilena Infectol 2012;29:587-94
   Google Scholar
• Moraes JC, Safadi MAP, Bricks LF, et al. Prevalence of meningococcal carriage among adolescents in Campinas, Brazil. Abstract presented at 31st Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID); 28th May–1st June 2013; Milan, Italy; 2013
   Google Scholar
• Valenzuela MT, Moreno G, Vaquero A, et al. [Emergencia de la cepa W135 causante de enfermedad meningocócica invasora en Chile 2012]. Rev Med Chile 2013;141:959-67
   PubMed Web of Science ®Google Scholar
• Ministerio de Salud Gobierno de Chile. Situación enfermedad meningocócica por serogrupo W-135. Available from: http://epi.minsal.cl/vigilancia-epidemiologica/enfermedades-de-notificacion-obligatoria/enfermedad-meningococica/
   Google Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009;27(Suppl 2):B51-63
   PubMed Web of Science ®Google Scholar
• Harrison LH, Pelton SI, Wilder-Smith A, et al. The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine 2011;29:3363-71
   PubMedGoogle Scholar
• John TJ, Gupta S, Chitkara AJ, et al. An overview of meningococcal disease in India: knowledge gaps and potential solutions. Vaccine 2013;31:2731-7
   PubMed Web of Science ®Google Scholar
• Sinclair D, Preziosi MP, Jacob John T, Greenwood B. The epidemiology of meningococcal disease in India. Trop Med Int Health 2010;15:1421-35
   PubMed Web of Science ®Google Scholar
• Khalil MK, Borrow R. Serogroup B meningococcal disease during Hajj: preparing for the worst scenario. Travel Med Infect Dis 2009;7:231-4
   PubMed Web of Science ®Google Scholar
• Health Protection Agency. Pilgrimage to Mecca (Hajj) 1992. Commun Dis Rep CDR Wkly 1992;2:43
   Google Scholar
• Al-Mazrou YY, Al-Jeffri MH, Abdalla MN, et al. Changes in epidemiological pattern of meningococcal disease in Saudi Arabia. Does it constitute a new challenge for prevention and control? Saudi Med J 2004;25:1410-13
   PubMed Web of Science ®Google Scholar
• Hajjeh R, Lingappa JR. Meningococcal disease in the Kingdom of Saudi Arabia: an evaluation of disease surveillance and control after an outbreak of serogroup W-135. CDC Rep 2000;23:2000
   Google Scholar
• World Health Organization. Meningococcal vaccines: polysaccharide and polysaccharide conjugate vaccines. Wkly Epidemiol Rec 2002;77:331-9
   Google Scholar
• Al-Mazrou YY, Khalil M, Borrow R, et al. Immunogenicity of a meningococcal ACYW135 polysaccharide vaccine in Saudi children aged under 5 years. Infect Immun 2005;73:2932-9
   PubMed Web of Science ®Google Scholar
• Greenwood B. Editorial: 100 years of epidemic meningitis in West Africa - has anything changed? Trop Med Int Health 2006;11:773-80
   PubMed Web of Science ®Google Scholar
• Artenstein AW, LaForce FM. Critical episodes in the understanding and control of epidemic meningococcal meningitis. Vaccine 2012;30:4701-7
   Google Scholar
• Leimkugel J, Hodgson A, Forgor AA, et al. Clonal waves of Neisseria colonisation and disease in the African meningitis belt: eight- year longitudinal study in northern Ghana. PLoS Med 2007;4:e101
   PubMed Web of Science ®Google Scholar
• Mueller JE, Yaro S, Njanpop-Lafourcade BM, et al. Study of a localized meningococcal meningitis epidemic in Burkina Faso: incidence, carriage, and immunity. J Infect Dis 2011;204:1787-95
   Google Scholar
• Trotter CL, Yaro S, Njanpop-Lafourcade BM, et al. Seroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A Neisseria meningitidis by age in Burkina Faso 2008. PLoS One 2013;8:e55486
   Google Scholar
• World Health Organization. Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec 2011;86:521-39
   PubMedGoogle Scholar
• Campagne G, Schuchat A, Djibo S, et al. Epidemiology of bacterial meningitis in Niamey, Niger, 1981-96. Bull World Health Organ 1999;77:499-508
   PubMed Web of Science ®Google Scholar
• Meningitis vaccine project. Available from: www.meningvax.org
   Google Scholar
• LaForce FM, Konde K, Viviani S, Préziosi MP. The Meningitis Vaccine Project. Vaccine 2007;25(Suppl 1):A97-A100
   PubMed Web of Science ®Google Scholar
• Whittle HC, Evans-Jones G, Onyewotu I, et al. Group C meningococcal meningitis in the northern savannah of Africa. Lancet 1975;1:1377
   Web of Science ®Google Scholar
• Broome CV, Rugh MA, Yada AA, et al. Epidemic group C meningococcal meningitis in Upper Volta, 1979. Bull World Health Organ 1983;61:325-30
   PubMed Web of Science ®Google Scholar
• Nathan N, Rose AM, Legros D, et al. Meningitis serogroup W135 outbreak, Burkina Faso, 2002. Emerg Infect Dis 2007;13:920-3
   PubMed Web of Science ®Google Scholar
• Traoré Y, Njanpop-Lafourcade BM, Adjogble KL, et al. The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005. Clin Infect Dis 2006;43:817-22
   PubMed Web of Science ®Google Scholar
• Karsany MS, Elshayeb AA, Saeed ES, et al. Patterns of meningococcal infection in Sudan with emergence of Neisseria meningitidis serogroup W135. East Mediterr Health J 2013;19:843-6
   Google Scholar
• Collard JM, Maman Z, Yacouba H, et al. Increase in Neisseria meningitidis serogroup W135, Niger, 2010. Emerg Infect Dis 2010;16:1496-8
   PubMed Web of Science ®Google Scholar
• Hossain MJ, Roca A, Mackenzie GA, et al. Serogroup W135 meningococcal disease, The Gambia, 2012. Emerg Infect Dis 2013;19:1507-10
   PubMed Web of Science ®Google Scholar
• Delrieu I, Yaro S, Tamekloé TA, et al. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS One 2011;6:e19513
   PubMed Web of Science ®Google Scholar
• Boisier P, Nicolas P, Djibo S, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007;44:657-63
   PubMed Web of Science ®Google Scholar
• Gagneux SP, Hodgson A, Smith TA, et al. Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. J Infect Dis 2002;185:618-26
   PubMed Web of Science ®Google Scholar
• World Health Organization. Outbreak news. Meningococcal disease, Uganda–update. Wkly Epidemiol Rec 2006;81:62
   Google Scholar
• Nakhla I, Frenck RWJr, Teleb NA, et al. The changing epidemiology of meningococcal meningitis after introduction of bivalent A/C polysaccharide vaccine into school-based vaccination programs in Egypt. Vaccine 2005;23:3288-93
   PubMed Web of Science ®Google Scholar
• Gaspar M, Leite F, Brumana L, et al. Epidemiology of meningococcal meningitis in Angola, 1994-2000. Epidemiol Infect 2001;127:421-4
   PubMedGoogle Scholar
• Moodley C, du Plessis M, Ndlangisa K, et al. Clonal analysis of Neisseria meningitidis serogroup B strains in South Africa, 2002 to 2006: emergence of new clone ST-4240/6688. J Clin Microbiol 2012;50:3678-86
   Google Scholar
• Woods CW, Armstrong G, Sackey SO, et al. Emergency vaccination against epidemic meningitis in Ghana: implications for the control of meningococcal disease in West Africa. Lancet 2000;355:30-3
   PubMed Web of Science ®Google Scholar
• Mohammed I, Obineche EN, Onyemelukwe GC, Zaruba K. Control of epidemic meningococcal meningitis by mass vaccination. I. Further epidemiological evaluation of groups A and C vaccines in northern Nigeria. J Infect 1984;9:190-6
   Google Scholar
• Kshirsagar N, Mur N, Thatte U, et al. Safety and immunogenicity of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine 2007;25S:A101-7
   Web of Science ®Google Scholar
• Sow S, Okoko BJ, Diallo A, et al. Immunogenicity, safety, and induction of immune memory of a new meningococcal group A conjugate vaccine in 1 to 29 year-old West Africans. N Engl J Med 2011;364:2293-304
   PubMed Web of Science ®Google Scholar
• Hirve S, Bavdekar A, Pandit A, et al. Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial. Vaccine 2012;30:6456-60
   PubMed Web of Science ®Google Scholar
• Frasch CE, Preziosi MP, LaForce FM. Development of a group A meningococcal conjugate vaccine, MenAfriVac(™). Hum Vaccin Immunother 2012;8:715-24
   PubMed Web of Science ®Google Scholar
• Collard JM, Issaka B, Zaneidou M, et al. Epidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccination. BMC Infect Dis 2013;13:576
   PubMed Web of Science ®Google Scholar
• Novak RT, Kambou JL, Diomandé FV, et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis 2012;12:757-64
   PubMed Web of Science ®Google Scholar
• Daugla DM, Gami JP, Gamougam K, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. Lancet 2014;383:40-7
   PubMed Web of Science ®Google Scholar
• Kristiansen PA, Diomandé F, Ba AK, et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis 2013;56:354-63
   PubMed Web of Science ®Google Scholar
• De Wals P. Meningococcal C vaccines. The Canadian experience. Pediatr Infect Dis J 2004;23:S280-4
   PubMedGoogle Scholar
• De Wals P, Nguyen VH, Erickson LJ, et al. Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease. Vaccine 2004;22:1233-40
   PubMed Web of Science ®Google Scholar
• De Wals P, Trottier P, Pepin J. Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: a model-based evaluation. Vaccine 2006;24:3500-4
   PubMed Web of Science ®Google Scholar
• De Wals P, Coudeville L, Trottier P, et al. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis. Vaccine 2007;25:5433-40
   PubMed Web of Science ®Google Scholar
• Ramsay ME, Andrews NJ, Trotter CL, et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003;326:365-6
   PubMed Web of Science ®Google Scholar
• De Wals P, Deceuninck G, Boulianne N, De Serres G. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA 2004;292:2491-4
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). [Practice Guideline]. MMWR Recomm Rep 2013;62(RR-2):1-28
   PubMed Web of Science ®Google Scholar
• MacNeil JR, Cohn AC, Zell ER, et al. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr Infect Dis J 2011;30:451-5
   PubMed Web of Science ®Google Scholar
• Siu T, Tang W, Dawar M, Patrick DM. Impact of routine immunization using meningococcal C conjugate vaccine on invasive meningococcal disease in British Columbia. Can J Public Health 2008;99:380-2
   Web of Science ®Google Scholar
• White CP, Scott J. Meningococcal serogroup C conjugate vaccination in Canada: how far have we progressed? How far do we have to go? Can J Public Health 2010;101:12-14
   PubMedGoogle Scholar
• de Greeff SC, de Melker HE, Spanjaard L, et al. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 2006;25:79-80
   PubMed Web of Science ®Google Scholar
• Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol 2005;162:89-100
   PubMed Web of Science ®Google Scholar